Developer docs
API playgroundTry for free, no card

Search company profiles

Sarepta Therapeutics

Full company profile

uuid000071p

Namestring
Sarepta Therapeutics
Legal namestring
Sarepta Therapeutics, Inc.
Websiteurl
sarepta.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Sarepta Therapeutics is a commercial-stage precision genetic medicine company developing therapeutics for rare neuromuscular diseases. Its portfolio centers on Duchenne muscular dystrophy (DMD), with four FDA-approved therapies: ELEVIDYS, an AAV-mediated gene therapy delivering micro-dystrophin; and three antisense oligonucleotide (PMO) exon-skipping products (EXONDYS 51, AMONDYS 45, VYONDYS 53) addressing distinct DMD mutations. The company is headquartered in Cambridge, Massachusetts, and operates gene therapy manufacturing in Columbus, Ohio (Genetic Therapies Center of Excellence within the $1.1B Nationwide Children's Innovation District) and Andover, Massachusetts. Its pipeline is expanding beyond DMD through an αvβ6 integrin-targeted siRNA delivery platform acquired from Arrowhead Pharmaceuticals in 2024 for $500M, supporting investigational programs in FSHD1 (SRP-1001), DM1 (SRP-1003), and Huntington's disease (SRP-1005).

Sarepta generates revenue primarily through one-time/perpetual pricing on ELEVIDYS and recurring pricing on its exon-skipping products, distributed via a US specialty pharmacy and treating-center channel and ex-US through the Roche/Chugai partnership (Japan commercial launch completed February 2026). FY2025 net product revenue reached $1.86B (up 16% YoY), with ELEVIDYS contributing $898.7M and total revenue including collaboration reaching approximately $2.2B. Customer support is delivered through SareptAssist and SareptAlly programs. International commercialization rights for ELEVIDYS are held by Roche, with a $40M milestone triggered by first Japan sale and a $325M declined-option payment recorded in FY2025 collaboration revenue.

The company faces a significant operational reset in 2025-2026 following patient deaths linked to ELEVIDYS: an FDA boxed warning for acute liver injury, shipment suspension for non-ambulatory patients, a CHMP negative opinion in the EU, a >35% workforce reduction, ENVISION study pause, revocation of the FDA platform technology designation, and the announced 2026 retirement of CEO Doug Ingram. Cash position of $953.8M at year-end 2025 and a $700M refinancing of convertibles to 2030 provide runway to navigate the transition while advancing the siRNA pipeline and resuming ex-US expansion.

Short descriptiontext

Sarepta Therapeutics is a precision genetic medicine company that develops and commercializes AAV gene therapies and antisense oligonucleotide treatments for rare neuromuscular diseases, primarily Duchenne muscular dystrophy, serving patients through specialty pharmacy channels in the US and via Roche/Chugai internationally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy drugs, rare disease therapeutics, precision genetic medicine, antisense oligonucleotide therapy, duchenne muscular dystrophy drugs
Industry4 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Genetic Medicine
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales
TypeOne Time License
Description

Net product revenue from four FDA-approved therapies: ELEVIDYS (gene therapy), EXONDYS 51, AMONDYS 45, VYONDYS 53 (exon-skipping). FY2025 net product revenues of $1.86 billion. Q1 2026 net product revenues of $330.5 million.

nai500.com
2Collaboration Revenue
TypeLicensing Royalties
Description

Includes Roche declined option payment ($325 million), milestone payments from partners ($40M from Roche for Japan commercial launch). Royalty revenue from international sales through Chugai.

in.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1ELEVIDYS gene therapy pricing
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

One-time gene therapy treatment with high upfront cost typical of CGT sector. Pricing not publicly disclosed. ICER cited concerns about accelerated approval pathway for Exondys 51 without confirmatory data.

fiercepharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1ELEVIDYS
Description

Gene therapy for Duchenne muscular dystrophy (delandistrogene moxeparvovec-rokl)

sarepta.com
+5 more records
Core offering1 text field

Sarepta Therapeutics is a precision genetic medicine company that discovers, develops, and commercializes therapies for rare neuromuscular diseases. The company has four FDA-approved products for Duchenne muscular dystrophy (DMD): ELEVIDYS gene therapy, and three antisense oligonucleotide exon-skipping therapies (EXONDYS 51, AMONDYS 45, VYONDYS 53). It is also advancing investigational siRNA programs for facioscapulohumeral muscular dystrophy type 1 (FSHD1), myotonic dystrophy type 1 (DM1), and Huntington's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3-year EMBARK: Statistically significant and clinically meaningful efficacy across NSAA, TTR, and 10MWR vs external control group
+3 more records
Product overview1 text field

Sarepta Therapeutics is a precision genetic medicine company with multiple approved therapies and an advancing pipeline. The company's commercial portfolio consists of four FDA-approved products for Duchenne muscular dystrophy: ELEVIDYS (gene therapy), EXONDYS 51, AMONDYS 45, and VYONDYS 53 (all exon-skipping ASO therapies targeting different DMD mutations). The pipeline includes investigational siRNA programs (SRP-1001 for FSHD1, SRP-1003 for DM1, SRP-1005 for Huntington's disease) developed on the company's RNA platform with proprietary αvβ6 integrin-targeted delivery technology. The company also maintains a gene therapy platform for AAV-mediated gene delivery.

Product and service7 records
1ELEVIDYS (delandistrogene moxeparvovec-rokl)
CategoryGene Therapy
Description

AAV-mediated gene therapy for Duchenne muscular dystrophy that delivers a gene encoding a shortened functional dystrophin protein (micro-dystrophin) to muscle cells. Approved for ambulatory patients aged 4 and older with confirmed DMD gene mutation; second-best selling gene therapy globally with 2025 sales of approximately $898.7 million.

2AMONDYS 45 (casimersen)
CategoryExon-Skipping Antisense Oligonucleotide
Description

Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 45 of the DMD gene to produce a truncated but functional dystrophin protein. Approved under FDA accelerated approval pathway; sNDA for traditional approval conversion planned by April 2026.

3VYONDYS 53 (golodirsen)
CategoryExon-Skipping Antisense Oligonucleotide
Description

Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 53 of the DMD gene to produce a truncated but functional dystrophin protein. Approved under FDA accelerated approval pathway; sNDA for traditional approval conversion planned by April 2026.

4EXONDYS 51 (eteplirsen)
CategoryExon-Skipping Antisense Oligonucleotide
Description

Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 51 of the DMD gene to produce a truncated but functional dystrophin protein. Sarepta's first approved therapy, approved under FDA accelerated approval pathway.

5SRP-1001
CategorysiRNA Therapeutic (Investigational)
Description

Investigational siRNA therapy using the αvβ6 integrin-targeted delivery platform for facioscapulohumeral muscular dystrophy type 1 (FSHD1), designed to reduce production of the DUX4 protein believed to play a central role in the disease. Currently in Phase 1/2 clinical trials.

6SRP-1003
CategorysiRNA Therapeutic (Investigational)
Description

Investigational siRNA therapy for myotonic dystrophy type 1 (DM1), targeting and suppressing DMPK (dystrophia myotonica protein kinase) in skeletal muscle. Licensed from Arrowhead Pharmaceuticals; currently in Phase 1/2 clinical trials.

7SRP-1005
CategorysiRNA Therapeutic (Investigational)
Description

Investigational siRNA therapeutic for Huntington's disease, with FDA approval of clinical trial application announced. Targets the huntingtin disease gene using the proprietary αvβ6 integrin-targeted delivery platform.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-06
Description

Roche holds commercial rights for ELEVIDYS outside the United States. Chugai Pharmaceutical (Roche Group company) handles Japan commercialization with reimbursement listing and commercial launch in February 2026. First commercial sale triggered $40M milestone payment to Sarepta. Roche is also conducting additional global Phase 3 trial for European approval resubmission.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Sarepta acquired exclusive rights to seven siRNA programs from Arrowhead Pharmaceuticals for $500 million in 2024. Programs include SRP-1001 (FSHD1) and SRP-1003 (DM1) which are now in Phase 1/2 clinical trials. Arrowhead's αvβ6 integrin-targeted delivery technology enables high muscle concentrations for siRNA therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for gene therapy research and manufacturing. Sarepta established Genetic Therapies Center of Excellence (GTCOE) in Columbus as part of $1.1 billion Innovation District. 25% of world's first eight gene therapy treatments originated at Nationwide Children's Hospital. Louise Rodino-Klapac was previously head of Laboratory for Gene Therapy Research at Nationwide Children's before joining Sarepta.

4Cooperative International Neuromuscular Research Group (CINRG)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

PPMD partnered with CINRG and global sponsors to advance expanded Duchenne Natural History Study (eDNHS). Study aims to gather long-term data on DMD to facilitate therapy development. Active enrollment across North America, Australia, and India.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AAV gene therapy platform company that has been both a Sarepta licensor and patent litigant, developing DMD and other rare disease gene therapies using NAV vectors.

TypeBroad incumbent
Description

Established rare disease biopharma with significant gene therapy experience (Roctavian for hemophilia A), competing in the broader rare neuromuscular and AAV gene therapy space.

TypeDirect peer
Description

Direct competitor in Duchenne muscular dystrophy with Translarna (ataluren) and Emflaza (deflazacort), serving the same DMD patient population with disease-modifying and symptomatic therapies.

TypeDirect peer
Description

Clinical-stage gene therapy developer focused on Duchenne muscular dystrophy with SGT-501, directly competing in AAV-microdystrophin approaches to DMD.

TypeDirect peer
Description

DMD-focused biotech developing CAP-1002 cell therapy for Duchenne, addressing overlapping patient segments and pursuing complementary disease-modifying mechanisms.

TypeDirect peer
Description

Antisense oligonucleotide pioneer and direct competitor in exon-skipping chemistry for DMD, with overlapping ASO platform technology.

TypeBroad incumbent
Description

siRNA platform leader and category-defining company; Sarepta's αvβ6 integrin delivery tech is licensed from Arrowhead, making Alnylam the closest RNA-interference analog for platform comparison.

TypeDirect peer
Description

siRNA platform company that licensed its αvβ6 integrin-targeted programs to Sarepta for $500M, providing both the underlying delivery technology and an ongoing co-development pipeline relationship.

TypeEmerging player
Description

Gene therapy company developing AMT-130 for Huntington's disease, directly competing with Sarepta's SRP-1005 program in the same indication.

TypeBroad incumbent
Description

Large-cap rare disease biopharma with a precision medicine and genetic therapy focus (including Casgevy in sickle cell/beta-thalassemia), representing a benchmark for scaled rare-disease commercial execution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sarepta Therapeutics

Rare Disease Genetic Medicinesarepta.com

Sarepta Therapeutics is a precision genetic medicine company that develops and commercializes AAV gene therapies and antisense oligonucleotide treatments for rare neuromuscular diseases, primarily Duchenne muscular dystrophy, serving patients through specialty pharmacy channels in the US and via Roche/Chugai internationally.

What Sarepta Therapeutics does

Sarepta Therapeutics is a commercial-stage precision genetic medicine company developing therapeutics for rare neuromuscular diseases. Its portfolio centers on Duchenne muscular dystrophy (DMD), with four FDA-approved therapies: ELEVIDYS, an AAV-mediated gene therapy delivering micro-dystrophin; and three antisense oligonucleotide (PMO) exon-skipping products (EXONDYS 51, AMONDYS 45, VYONDYS 53) addressing distinct DMD mutations. The company is headquartered in Cambridge, Massachusetts, and operates gene therapy manufacturing in Columbus, Ohio (Genetic Therapies Center of Excellence within the $1.1B Nationwide Children's Innovation District) and Andover, Massachusetts. Its pipeline is expanding beyond DMD through an αvβ6 integrin-targeted siRNA delivery platform acquired from Arrowhead Pharmaceuticals in 2024 for $500M, supporting investigational programs in FSHD1 (SRP-1001), DM1 (SRP-1003), and Huntington's disease (SRP-1005).

Sarepta generates revenue primarily through one-time/perpetual pricing on ELEVIDYS and recurring pricing on its exon-skipping products, distributed via a US specialty pharmacy and treating-center channel and ex-US through the Roche/Chugai partnership (Japan commercial launch completed February 2026). FY2025 net product revenue reached $1.86B (up 16% YoY), with ELEVIDYS contributing $898.7M and total revenue including collaboration reaching approximately $2.2B. Customer support is delivered through SareptAssist and SareptAlly programs. International commercialization rights for ELEVIDYS are held by Roche, with a $40M milestone triggered by first Japan sale and a $325M declined-option payment recorded in FY2025 collaboration revenue.

The company faces a significant operational reset in 2025-2026 following patient deaths linked to ELEVIDYS: an FDA boxed warning for acute liver injury, shipment suspension for non-ambulatory patients, a CHMP negative opinion in the EU, a >35% workforce reduction, ENVISION study pause, revocation of the FDA platform technology designation, and the announced 2026 retirement of CEO Doug Ingram. Cash position of $953.8M at year-end 2025 and a $700M refinancing of convertibles to 2030 provide runway to navigate the transition while advancing the siRNA pipeline and resuming ex-US expansion.

Sarepta Therapeutics firmographics

Firmographics
Name
Sarepta Therapeutics
Legal name
Sarepta Therapeutics, Inc.
Website
https://sarepta.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Sarepta Therapeutics is a precision genetic medicine company that develops and commercializes AAV gene therapies and antisense oligonucleotide treatments for rare neuromuscular diseases, primarily Duchenne muscular dystrophy, serving patients through specialty pharmacy channels in the US and via Roche/Chugai internationally.
Ownership category
akta.pro rank

Sarepta Therapeutics industry classification

Industry
Product category
Rare Disease Genetic Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)

Keywords

  • Gene therapy drugs
  • Rare disease therapeutics
  • Precision genetic medicine
  • Antisense oligonucleotide therapy
  • Duchenne muscular dystrophy drugs

Where Sarepta Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Sarepta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Sales: Net product revenue from four FDA-approved therapies: ELEVIDYS (gene therapy), EXONDYS 51, AMONDYS 45, VYONDYS 53 (exon-skipping). FY2025 net product revenues of $1.86 billion. Q1 2026 net product revenues of $330.5 million.
  2. Collaboration Revenue: Includes Roche declined option payment ($325 million), milestone payments from partners ($40M from Roche for Japan commercial launch). Royalty revenue from international sales through Chugai.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseELEVIDYS gene therapy pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Sarepta Therapeutics product offering

Product offering

Core offering

Sarepta Therapeutics is a precision genetic medicine company that discovers, develops, and commercializes therapies for rare neuromuscular diseases. The company has four FDA-approved products for Duchenne muscular dystrophy (DMD): ELEVIDYS gene therapy, and three antisense oligonucleotide exon-skipping therapies (EXONDYS 51, AMONDYS 45, VYONDYS 53). It is also advancing investigational siRNA programs for facioscapulohumeral muscular dystrophy type 1 (FSHD1), myotonic dystrophy type 1 (DM1), and Huntington's disease.

Product overview

Sarepta Therapeutics is a precision genetic medicine company with multiple approved therapies and an advancing pipeline. The company's commercial portfolio consists of four FDA-approved products for Duchenne muscular dystrophy: ELEVIDYS (gene therapy), EXONDYS 51, AMONDYS 45, and VYONDYS 53 (all exon-skipping ASO therapies targeting different DMD mutations). The pipeline includes investigational siRNA programs (SRP-1001 for FSHD1, SRP-1003 for DM1, SRP-1005 for Huntington's disease) developed on the company's RNA platform with proprietary αvβ6 integrin-targeted delivery technology. The company also maintains a gene therapy platform for AAV-mediated gene delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • ELEVIDYS: Gene therapy for Duchenne muscular dystrophy (delandistrogene moxeparvovec-rokl)
  • EXONDYS 51
  • VYONDYS 53
  • AMONDYS 45
  • SareptAssist
  • SareptAlly

Products and services

  • ELEVIDYS (delandistrogene moxeparvovec-rokl) AAV-mediated gene therapy for Duchenne muscular dystrophy that delivers a gene encoding a shortened functional dystrophin protein (micro-dystrophin) to muscle cells. Approved for ambulatory patients aged 4 and older with confirmed DMD gene mutation; second-best selling gene therapy globally with 2025 sales of approximately $898.7 million.
  • AMONDYS 45 (casimersen) Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 45 of the DMD gene to produce a truncated but functional dystrophin protein. Approved under FDA accelerated approval pathway; sNDA for traditional approval conversion planned by April 2026.
  • VYONDYS 53 (golodirsen) Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 53 of the DMD gene to produce a truncated but functional dystrophin protein. Approved under FDA accelerated approval pathway; sNDA for traditional approval conversion planned by April 2026.
  • EXONDYS 51 (eteplirsen) Antisense oligonucleotide (ASO) exon-skipping therapy for Duchenne muscular dystrophy, designed to skip exon 51 of the DMD gene to produce a truncated but functional dystrophin protein. Sarepta's first approved therapy, approved under FDA accelerated approval pathway.
  • SRP-1001 Investigational siRNA therapy using the αvβ6 integrin-targeted delivery platform for facioscapulohumeral muscular dystrophy type 1 (FSHD1), designed to reduce production of the DUX4 protein believed to play a central role in the disease. Currently in Phase 1/2 clinical trials.
  • SRP-1003 Investigational siRNA therapy for myotonic dystrophy type 1 (DM1), targeting and suppressing DMPK (dystrophia myotonica protein kinase) in skeletal muscle. Licensed from Arrowhead Pharmaceuticals; currently in Phase 1/2 clinical trials.
  • SRP-1005 Investigational siRNA therapeutic for Huntington's disease, with FDA approval of clinical trial application announced. Targets the huntingtin disease gene using the proprietary αvβ6 integrin-targeted delivery platform.

Quantifiable outcome

  • 3-year EMBARK: Statistically significant and clinically meaningful efficacy across NSAA, TTR, and 10MWR vs external control group
  • +3 more outcomes

Companies that use Sarepta Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Sarepta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sarepta Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Roche / Chugai PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 6 March 2026Roche holds commercial rights for ELEVIDYS outside the United States. Chugai Pharmaceutical (Roche Group company) handles Japan commercialization with reimbursement listing and commercial launch in February 2026. First commercial sale triggered $40M milestone payment to Sarepta. Roche is also conducting additional global Phase 3 trial for European approval resubmission.
  • Arrowhead PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024Sarepta acquired exclusive rights to seven siRNA programs from Arrowhead Pharmaceuticals for $500 million in 2024. Programs include SRP-1001 (FSHD1) and SRP-1003 (DM1) which are now in Phase 1/2 clinical trials. Arrowhead's αvβ6 integrin-targeted delivery technology enables high muscle concentrations for siRNA therapeutics.
  • Nationwide Children's Hospital (Columbus, Ohio)coreStrategic or Co-development PartnerPartnership for gene therapy research and manufacturing. Sarepta established Genetic Therapies Center of Excellence (GTCOE) in Columbus as part of $1.1 billion Innovation District. 25% of world's first eight gene therapy treatments originated at Nationwide Children's Hospital. Louise Rodino-Klapac was previously head of Laboratory for Gene Therapy Research at Nationwide Children's before joining Sarepta.
  • Cooperative International Neuromuscular Research Group (CINRG)minorStrategic or Co-development PartnerPPMD partnered with CINRG and global sponsors to advance expanded Duchenne Natural History Study (eDNHS). Study aims to gather long-term data on DMD to facilitate therapy development. Active enrollment across North America, Australia, and India.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Sarepta Therapeutics competitors and assessment

Company assessment

Direct peers

  • Regenxbio: AAV gene therapy platform company that has been both a Sarepta licensor and patent litigant, developing DMD and other rare disease gene therapies using NAV vectors.
  • PTC Therapeutics: Direct competitor in Duchenne muscular dystrophy with Translarna (ataluren) and Emflaza (deflazacort), serving the same DMD patient population with disease-modifying and symptomatic therapies.
  • Solid Biosciences: Clinical-stage gene therapy developer focused on Duchenne muscular dystrophy with SGT-501, directly competing in AAV-microdystrophin approaches to DMD.
  • Capricor Therapeutics: DMD-focused biotech developing CAP-1002 cell therapy for Duchenne, addressing overlapping patient segments and pursuing complementary disease-modifying mechanisms.
  • Ionis Pharmaceuticals: Antisense oligonucleotide pioneer and direct competitor in exon-skipping chemistry for DMD, with overlapping ASO platform technology.
  • Arrowhead Pharmaceuticals: siRNA platform company that licensed its αvβ6 integrin-targeted programs to Sarepta for $500M, providing both the underlying delivery technology and an ongoing co-development pipeline relationship.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biopharma with significant gene therapy experience (Roctavian for hemophilia A), competing in the broader rare neuromuscular and AAV gene therapy space.
  • Alnylam Pharmaceuticals: siRNA platform leader and category-defining company; Sarepta's αvβ6 integrin delivery tech is licensed from Arrowhead, making Alnylam the closest RNA-interference analog for platform comparison.
  • Vertex Pharmaceuticals: Large-cap rare disease biopharma with a precision medicine and genetic therapy focus (including Casgevy in sickle cell/beta-thalassemia), representing a benchmark for scaled rare-disease commercial execution.

Emerging players

  • uniQure: Gene therapy company developing AMT-130 for Huntington's disease, directly competing with Sarepta's SRP-1005 program in the same indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

Sarepta Therapeutics social profiles

Digital presence

Sarepta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sarepta Therapeutics leadership team

Management profile

Number of profiles

Profiles20 records

Sarepta Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sarepta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sarepta Therapeutics M&A and investment

M&A and investment

M&A3 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sarepta Therapeutics

What does Sarepta Therapeutics do?

Sarepta Therapeutics is a precision genetic medicine company that discovers, develops, and commercializes therapies for rare neuromuscular diseases. The company has four FDA-approved products for Duchenne muscular dystrophy (DMD): ELEVIDYS gene therapy, and three antisense oligonucleotide exon-skipping therapies (EXONDYS 51, AMONDYS 45, VYONDYS 53). It is also advancing investigational siRNA programs for facioscapulohumeral muscular dystrophy type 1 (FSHD1), myotonic dystrophy type 1 (DM1), and Huntington's disease.

Is Sarepta Therapeutics a public or private company?

Sarepta Therapeutics is a public company. It is classified as public and is currently operating.

When was Sarepta Therapeutics founded?

Sarepta Therapeutics was founded in 1987. It employs 1,001 to 5,000 people.

Where is Sarepta Therapeutics based?

Sarepta Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Sarepta Therapeutics make money?

Two revenue lines are on record. Product Sales are the primary driver. The others are collaboration Revenue.

Who are Sarepta Therapeutics's main competitors?

Direct peers on record are Regenxbio, PTC Therapeutics, Solid Biosciences, Capricor Therapeutics, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals. Broad incumbents are BioMarin Pharmaceutical, Alnylam Pharmaceuticals and Vertex Pharmaceuticals. uniQure is listed as an emerging player.

Does Sarepta Therapeutics have an API?

No public API is recorded for Sarepta Therapeutics.

What industry is Sarepta Therapeutics in?

Sarepta Therapeutics's product category is Rare Disease Genetic Medicine. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewJP Morgan maintains Sarepta Therapeutics at Neutral, raises price target to $22 from $20JP Morgan maintained Sarepta Therapeutics at Neutral and raised its price target to $22 from $20, a 10% increase. The target implies a 51.4% upside from the Nov 18 close of $14.53.Simply Wall StWhy Sarepta Therapeutics (SRPT) Is Getting Attention TodaySarepta Therapeutics raised its 2026 net product revenue guidance to $1.25–$1.3 billion, increasing the low end by $50 million. The stock is down 24.59% year-to-date, while analysts see a fair value of $21.73. The company's cash flow-positive Duchenne portfolio and siRNA program support future growth.Simply Wall StRaised Revenue Guidance Might Change The Case For Investing In Sarepta Stock (SRPT)Sarepta Therapeutics raised its 2026 total net product revenue guidance to $1.25b-$1.3b, lifting the low end by $50 million. The company reported Q3 2026 revenue of $381.35 million and a quarterly net loss of $28.46 million, while nine-month net income turned positive at $297.61 million.MarketBeatSarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs AdvanceSarepta Therapeutics CEO Michael Severino expects its myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy programs to enter registrational studies within 12 months, and Huntington's disease program to show biological activity by mid-2026. He sees 2027 as transformational, with Duchenne cash flow funding development without equity raises.Investing.comSarepta at Guggenheim conference: cash flow funds a broad pipelineSarepta Therapeutics outlined its Duchenne franchise and pipeline at the Guggenheim conference, saying its commercial business funds development without equity raises. The company expects near-term data in DM1 and FSHD, with Huntington's proof-of-biology around mid-2025, and CEO Michael Severino said 2027 could be transformational.Seeking AlphaSarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call TranscriptSarepta Therapeutics reported its Q3 2026 financial results on November 5, 2026, with CEO Mike Severino and CFO Ryan Wong leading the call. The company plans to file its Form 10-Q with the SEC today. The transcript includes remarks from executives and analyst questions.American Banking and Market NewsSarepta Therapeutics, Inc. $SRPT Shares Bought by CenterBook Partners LPCenterBook Partners LP increased its stake in Sarepta Therapeutics by 232.3% in Q3, buying 107,560 shares. Sarepta reported Q3 EPS of $0.13, beating consensus, but revenue fell 4.5% year over year. Analysts have an average "Reduce" rating with a $23.40 target.Simply Wall StWill Narrower Losses Change Sarepta Therapeutics Stock NarrativeSarepta Therapeutics reported Q3 2026 revenue of $381.35 million and a net loss of $28.46 million, down from $50.57 million a year earlier. Year-to-date 2026 net income turned to $297.61 million from a $301.18 million loss, reflecting tighter cost control. Analysts project revenue of $1.3 billion and earnings of $36.4 million by 2029.TradingViewRBC Capital maintains Sarepta Therapeutics at Sector Perform, raises price target to $18 from $17RBC Capital maintained Sarepta Therapeutics at Sector Perform and raised its price target to $18 from $17, a 5.9% increase. The target implies 2.4% upside from the Nov 5 close of $17.57.BioSpaceSarepta’s new CEO confident in clinical execution as DMD competitors close inSarepta Therapeutics' new CEO Michael Severino expressed confidence in the company's clinical trial execution, citing improved effect sizes and site selection. He noted upcoming siRNA programs and a February 2027 FDA decision on exon-skippers, while acknowledging competition from Dyne Therapeutics. Elevidys sales declined to $83.5 million in the quarter, but the company expects stabilization.